By combining ibrutinib and venetoclax, which are two targeted oral therapies with different mechanisms of action, a major extension in progression-free survival (PFS) can be achieved in advanced mantle cell lymphoma (R/R MCL). This finding comes from an international, phase 3, placebo-controlled trial called SYMPATICO. The study was reported at the 2023 annual meeting of the American Society of Hematology (abstract LBA2).
Based on the degree of benefit, “this combination should be the new